Transmedics Group Stock

Transmedics Group ROE

The Return on Equity (ROE) of Transmedics Group (TMDX) as of Aug 12, 2026 is 40.22 %. In the previous year, Return on Equity (ROE) was 15.51 % — a change of 159.27% (higher).

ROE

40.22 %

YoY

159.27%

Last updated:

In 2026, Transmedics Group's return on equity (ROE) was 40.22 %, a 159.27% increase from the 15.51 % ROE in the previous year.

Access this data via the Eulerpool API

Transmedics Group Stock analysis

What does Transmedics Group do? Transmedics Group Inc is a company dedicated to the development and manufacturing of medical devices for organ transplantation. The company was founded in 1998 and is headquartered in Andover, Massachusetts, USA. Transmedics' business model is based on offering a unique and innovative technology for organ preservation during transport from donor to recipient. The patented Organ Care System (OCS) platform includes a range of state-of-the-art medical devices specifically designed for organ transport. Transmedics' Organ Care System includes three main devices: OCS Heart, OCS Lung, and OCS Liver. Each device is tailored for organ preparation and transport, providing individualized support based on the specific requirements of each organ and different transfer protocols. The OCS technology uses hypothermic (cold) perfusion to preserve the organ during transport. By continuously monitoring and supporting the organ's physiological functions, the OCS system can improve the survival rate of donor organs while reducing the time spent outside the body. Transmedics also offers comprehensive services, including the availability of OCS devices and qualified personnel to provide support throughout the transplantation process. Transmedics' customers include leading transplant centers and hospitals worldwide. The company works closely with these customers to ensure that its OCS devices meet the specific requirements of each transplantation program and help them achieve more successful transplantations. Transmedics' history is marked by a passion for improving transplantation medicine and saving lives through the provision of advanced technologies and solutions. The company has made significant progress in recent years and has experienced strong growth in all areas. Transmedics has also received a number of awards and recognition for its commitment to improving transplantation medicine. For example, in 2020, the company received the Red Herring Top 100 Global Award and was recognized for the seventh consecutive year as one of the fastest-growing companies by Deloitte. Overall, Transmedics is a leading provider of innovative medical devices for transplantation medicine. Through its organic technology and comprehensive service, the company supports transplant centers and hospitals worldwide in performing more successful transplantations and saving patients' lives. Transmedics Group is one of the most popular companies on Eulerpool.

ROE Details

Decoding Transmedics Group's Return on Equity (ROE)

Transmedics Group's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Transmedics Group's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Transmedics Group's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Transmedics Group’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Transmedics Group stock

Return on Equity (ROE) of Transmedics Group is 40.22 % in 2026.

Return on Equity (ROE) of Transmedics Group changed from 15.51 % to 40.22 %, representing a 159.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Transmedics Group since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Transmedics Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Transmedics Group

All Key Metrics — Transmedics Group